Our previous meta-analysis showed that HCC patients with a mutant p53 gene or p53 protein overexpression had a higher risk of mortality and tumor recurrence than those with wild-type p53 status or low/no p53 expression, which can inform clinical decision-making in HCC [3]. This evidence concerns the gene TP53 and hepatocellular carcinoma.